Highly accurate Alzheimer’s blood test a ‘breakthrough,’ observers say
By
Alicia Lasek
Jul 30, 2020
The experimental blood test rivals the accuracy of standard diagnostic methods and may soon prove to be a cost-effective, accessible tool in the clinical setting, according to some in the scientific community.
Genetic testing opens can of worms for Alzheimer’s patients
By
Elizabeth Newman
Mar 25, 2015
Healthcare professionals tend to have a belief in facts, and as a corollary believe in conventional wisdom that knowledge is power. Of course, what people SAY they want to know and how they actually act...
‘Awakenings’ in advanced dementia patients inspire search for a cause
By
Alicia Lasek
Aug 07, 2019
Scientists have begun a search for the cause of a phenomena where people with late-stage Alzheimer’s disease are very lucid near the end of life.
NIH highlights decade of Alzheimer’s advancements tied to small business investments
By
Alicia Lasek
Aug 11, 2021
A new paper showcases the results of 11 years of federal investment in dementia research, including advancements in care intervention, diagnostics and therapeutics.
Scientists say they’ve zeroed in on a cause of Alzheimer’s
By
Alicia Lasek
Dec 03, 2021
Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.
Mirtazapine does not reduce agitation in dementia patients
Nov 03, 2021
In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo
Dementia signs, symptoms may be different for Latinos, researchers say
By
Alicia Lasek
May 27, 2021
Cultural practices and disease processes may explain why Latino adults with dementia experience faster functional decline and higher rates of depression and anxiety, investigators say.
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
The disease that keeps on taking
By
John O'Connor
Aug 06, 2012
There is no way to tally the full cost of Alzheimer’s disease, a life robbing condition that now claims more than 5 million victims nationwide. But what can be put on a ledger sheet is sobering....
COVID-19 patients face higher risk of neurodegenerative disorders: study
By
Alicia Lasek (f3)
Jul 01, 2022
People who test positive for COVID-19 are at an increased risk of Alzheimer’s disease, Parkinson’s disease and ischemic stroke, a large new study finds.